

Birgit Georger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9269726/publications.pdf>

Version: 2024-02-01

105
papers

4,738
citations

117625

34
h-index

106344

65
g-index

106
all docs

106
docs citations

106
times ranked

6392
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, 997-1007.	1.2	72
2	Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. <i>Cancer Research</i> , 2022, 82, 974-985.	0.9	14
3	Rapid and highly sensitive approach for multiplexed somatic fusion detection. <i>Modern Pathology</i> , 2022, 35, 1022-1033.	5.5	2
4	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. <i>Cancer Discovery</i> , 2022, 12, 1266-1281.	9.4	67
5	Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement. <i>Haematologica</i> , 2022, 107, 2255-2260.	3.5	5
6	HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours. <i>Neuro-Oncology</i> , 2022, 24, i64-i64.	1.2	1
7	Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2010-2010.	1.6	4
8	Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset. <i>Journal of Clinical Oncology</i> , 2022, 40, 10030-10030.	1.6	4
9	Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3730-3740.	1.6	22
10	Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10058-TPS10058.	1.6	2
11	Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting. <i>European Journal of Cancer</i> , 2021, 144, 113-122.	2.8	18
12	Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28666.	1.5	2
13	Clinical and molecular analysis of smoothed inhibitors in Sonic Hedgehog medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, v097.	0.7	5
14	NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. <i>JCO Precision Oncology</i> , 2021, 5, 450-454.	3.0	2
15	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	2.0	9
16	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. <i>American Journal of Surgical Pathology</i> , 2021, 45, 854-867.	3.7	12
17	Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. <i>Tumori</i> , 2021, 107, 276-281.	1.1	6
18	MEVITEM – a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. <i>Neuro-Oncology</i> , 2021, 23, 1949-1960.	1.2	20

#	ARTICLE	IF	CITATIONS
19	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÅ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. <i>European Journal of Cancer</i> , 2021, 150, 53-62.	2.8	33
20	Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. <i>BMC Cancer</i> , 2021, 21, 833.	2.6	5
21	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSÅ©-ESMART Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3546-3560.	1.6	17
22	Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. <i>European Journal of Cancer</i> , 2021, 153, 142-152.	2.8	12
23	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÅ©-ESMART trial. <i>European Journal of Cancer</i> , 2021, 157, 268-277.	2.8	19
24	Immunodynamics of explanted human tumors for immunoœoncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	6.9	9
25	Precision Cancer Medicine: Large Studies Indicate Steady Progress. <i>Cancer Discovery</i> , 2021, 11, 2677-2678.	9.4	6
26	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	10.7	37
27	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28032.	1.5	17
28	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1œ2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
29	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1œ2 study. <i>Lancet Oncology</i> , The, 2020, 21, 134-144.	10.7	103
30	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa075.	0.7	2
31	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020, 141, 82-91.	2.8	15
32	SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. <i>Cancers</i> , 2020, 12, 3051.	3.7	4
33	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
34	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
35	Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma œ Author's reply. <i>Lancet Oncology</i> , The, 2020, 21, e127.	10.7	1
36	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52

#	ARTICLE	IF	CITATIONS
37	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. <i>European Journal of Cancer</i> , 2020, 130, 72-80.	2.8	18
38	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318.	7.0	28
39	Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10507-10507.	1.6	6
40	LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2020, 22, iii375-iii375.	1.2	1
41	EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii305-iii305.	1.2	0
42	In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice. <i>Cancers</i> , 2019, 11, 997.	3.7	10
43	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27900.	1.5	6
44	Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression. <i>Oncogene</i> , 2019, 38, 7200-7215.	5.9	7
45	Sequential or combined designs for Phase I/II clinical trials? A simulation study. <i>Clinical Trials</i> , 2019, 16, 635-644.	1.6	7
46	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	7.0	128
47	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7294-7302.	7.0	63
48	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. <i>Frontiers in Oncology</i> , 2019, 9, 1271.	2.8	12
49	Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine. <i>Molecular Therapy</i> , 2019, 27, 200-218.	8.2	26
50	Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27487.	1.5	5
51	Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10010-10010.	1.6	14
52	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10018-10018.	1.6	3
53	Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2006-2006.	1.6	60
54	Establishment and characterization of <i>in vivo</i> orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and <sc>NSG</sc> mice. <i>Cancer Medicine</i> , 2018, 7, 665-676.	2.8	12

#	ARTICLE	IF	CITATIONS
55	Precision medicine in pediatric oncology. <i>Current Opinion in Pediatrics</i> , 2018, 30, 17-24.	2.0	102
56	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". <i>European Journal of Cancer</i> , 2018, 94, 156-167.	2.8	35
57	Outcome of children and adolescents with central nervous system tumors in phase I trials. <i>Journal of Neuro-Oncology</i> , 2018, 137, 83-92.	2.9	2
58	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. <i>European Journal of Cancer</i> , 2018, 100, 27-34.	2.8	22
59	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600 mutant relapsed refractory low-grade glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 10506-10506.	1.6	17
60	KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 10525-10525.	1.6	10
61	Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. <i>International Journal of Oncology</i> , 2017, 50, 203-211.	3.3	27
62	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2433-2441.	7.0	134
63	Early phase clinical trials of anticancer agents in children and adolescents " an ITCC perspective. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 497-507.	27.6	61
64	Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. <i>Cancer Genetics</i> , 2017, 212-213, 32-37.	0.4	19
65	Assessment of programmed death ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <i>Cancer</i> , 2017, 123, 3807-3815.	4.1	135
66	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	5.0	28
67	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. <i>European Journal of Cancer</i> , 2017, 86, 275-284.	2.8	4
68	Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). <i>European Journal of Cancer</i> , 2017, 83, 177-184.	2.8	70
69	Proteomic Analysis of Neuroblastoma-Derived Exosomes: New Insights into a Metastatic Signature. <i>Proteomics</i> , 2017, 17, 1600430.	2.2	32
70	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
71	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. <i>European Journal of Cancer</i> , 2017, 86, 358-363.	2.8	72
72	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology</i> , The, 2017, 18, e394-e404.	10.7	45

#	ARTICLE	IF	CITATIONS
73	Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPE European phase II clinical trials. <i>Pediatric Blood and Cancer</i> , 2017, 64, 25-31.	1.5	61
74	Phase 1 study of dalotuzumab monotherapy and ridaforolimus+dalotuzumab combination therapy in paediatric patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 62, 9-17.	2.8	20
75	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. <i>European Journal of Cancer</i> , 2016, 67, 130-140.	2.8	17
76	Implementation of mechanism of action biology-driven early drug development for children with cancer. <i>European Journal of Cancer</i> , 2016, 62, 124-131.	2.8	58
77	Innovations for phase I dose-finding designs in pediatric oncology clinical trials. <i>Contemporary Clinical Trials</i> , 2016, 47, 217-227.	1.8	29
78	Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10551-10551.	1.6	4
79	Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I trial (NCT01887522).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10555-10555.	1.6	2
80	A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. <i>Oncotarget</i> , 2016, 7, 84736-84747.	1.8	22
81	Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. <i>Anticancer Research</i> , 2016, 36, 599-609.	1.1	19
82	Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e102-e110.	0.6	31
83	Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10004-10004.	1.6	27
84	Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10005-10005.	1.6	23
85	Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. <i>PLoS ONE</i> , 2015, 10, e0142612.	2.5	40
86	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer</i> , 2014, 120, 2448-2456.	4.1	158
87	Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1101-1103.	1.5	125
88	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. <i>European Journal of Cancer</i> , 2014, 50, 170-177.	2.8	47
89	Establishment and characterization of new orthotopic and metastatic neuroblastoma models. <i>In Vivo</i> , 2014, 28, 425-34.	1.3	20
90	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. <i>Journal of Neuro-Oncology</i> , 2013, 113, 127-134.	2.9	9

#	ARTICLE	IF	CITATIONS
91	A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adultsâ€™™ trials. <i>European Journal of Cancer</i> , 2013, 49, 2392-2402.	2.8	51
92	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. <i>Neuro-Oncology</i> , 2013, 15, 1236-1243.	1.2	41
93	Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?. <i>Clinical Cancer Research</i> , 2013, 19, 1315-1325.	7.0	48
94	Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. <i>European Journal of Cancer</i> , 2012, 48, 253-262.	2.8	130
95	A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. <i>European Journal of Cancer</i> , 2012, 48, 289-296.	2.8	30
96	Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas. <i>PLoS ONE</i> , 2012, 7, e30313.	2.5	200
97	A phase I/II study of LDE225, a smoothed (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9519-9519.	1.6	21
98	The selective VEGFR1â€™ inhibitor axitinib (AGâ€™13736) shows antitumor activity in human neuroblastoma xenografts. <i>International Journal of Cancer</i> , 2011, 128, 2748-2758.	5.1	48
99	Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. <i>Clinical Cancer Research</i> , 2011, 17, 4862-4871.	7.0	35
100	Preliminary Efficacy of the Anti-Insulinâ€™ Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4534-4540.	1.6	195
101	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4541-4547.	1.6	293
102	The role of the â€™innovative therapies for children with cancerâ€™™ (ITCC) European consortium. <i>Cancer Treatment Reviews</i> , 2010, 36, 328-334.	7.7	58
103	Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. <i>European Journal of Cancer</i> , 2010, 46, 2763-2770.	2.8	20
104	Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. <i>European Journal of Cancer</i> , 2010, 46, 3251-3262.	2.8	24
105	EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. <i>International Journal of Cancer</i> , 2008, 123, 209-216.	5.1	56